Blair William & Co. IL Buys 19,433 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

Blair William & Co. IL grew its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 15.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 143,476 shares of the company's stock after buying an additional 19,433 shares during the quarter. Blair William & Co. IL owned approximately 0.07% of Cellebrite DI worth $3,161,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Quarry LP acquired a new position in shares of Cellebrite DI in the third quarter worth approximately $27,000. R Squared Ltd bought a new position in Cellebrite DI during the fourth quarter worth $100,000. Polen Capital Management LLC acquired a new position in Cellebrite DI in the fourth quarter valued at $222,000. Victory Capital Management Inc. bought a new stake in Cellebrite DI during the fourth quarter valued at $234,000. Finally, HighTower Advisors LLC acquired a new stake in Cellebrite DI during the 4th quarter worth about $274,000. 45.88% of the stock is currently owned by institutional investors and hedge funds.

Cellebrite DI Trading Down 5.6 %

Shares of CLBT traded down $1.06 during trading hours on Friday, reaching $17.71. 1,386,431 shares of the company's stock traded hands, compared to its average volume of 1,397,574. The firm's 50 day simple moving average is $20.41 and its 200-day simple moving average is $19.95. The stock has a market cap of $4.24 billion, a PE ratio of -12.74, a price-to-earnings-growth ratio of 4.27 and a beta of 1.44. Cellebrite DI Ltd. has a 12 month low of $10.25 and a 12 month high of $26.30.

Remove Ads

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. As a group, analysts expect that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CLBT has been the topic of several research analyst reports. Lake Street Capital increased their target price on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a research note on Friday, February 14th. Needham & Company LLC reissued a "buy" rating and set a $28.00 price objective on shares of Cellebrite DI in a research report on Wednesday. Finally, JPMorgan Chase & Co. boosted their target price on Cellebrite DI from $24.00 to $28.00 and gave the company an "overweight" rating in a research report on Tuesday, February 11th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $23.43.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.